Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Bone. 2012 Aug 14;51(5):835–846. doi: 10.1016/j.bone.2012.08.111

Figure 1.

Figure 1

Experimental protocol. Androgen therapy with the non-aromatizable androgen DHT was administered for the final 6 weeks of study in both paradigms. A. In prevention-HT, ORX was performed at 5 months of age and treatment initiated immediately. B. In the therapeutic-LT studies, ORX was performed at 3 months of age and treatment delayed for 2 months to allow a period of hypogonadal bone loss. Analysis in both groups was performed on 6½ month old mice.